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Research
Furan is an important industrial compound 
that was recently found in a number of heated 
food items, including baby food (Food and 
Drug Administration 2004). Furan has been 
reported to cause liver tumors characteristic 
of hepato  cellular carcinoma and cholangio­
carcinoma (CC) in both male and female 
rats at doses of 2, 4, or 8 mg/kg body weight 
(bw), 5 days a week for 2 years [National 
Toxicology Program (NTP) 1993]. Male rats 
treated with 30 mg/kg bw furan for 3 months 
develop cholangiofibrosis, which in some cases 
progressed to tumors after 9 or 15 months 
without further treatment (Maronpot et al. 
1991). There are no tumorigenicity data at 
doses < 2 mg/kg bw. Bearing in mind that 
CC is the next most common primary hepatic 
malignancy in humans after hepato  cellular 
carcinoma and that it is associated with high 
mortality, an assessment of the effects of furan 
relevant to carcinogenicity at doses < 2 mg/kg 
is essential. A recent evaluation by the Joint 
Food and Agriculture Organization/World 
Health Organization Expert Committee on 
Food Additives (JECFA) also indicated a 
human health concern (JECFA 2010).
The mechanisms of furan carcinogenicity   
are still not well understood. Furan has shown 
negative results in a number of in vitro geno­
toxicity assays (Mortelmans et al. 1986), and 
an in vivo DNA binding study provided no 
evidence for covalent binding of furan to 
DNA (Burka et al. 1991). Wilson et al. (1992) 
found no evidence of increased DNA synthesis 
in an in vivo DNA repair assay, and furan was 
not clastogenic or aneugenic in either in vivo 
or in vitro studies (Durling et al. 2007). 
Kellert et al. (2008) demon  strated that furan 
was not genotoxic when added directly to 
mouse lymphoma cells, although its metabo­
lite cis­2­butene­1,4­dial was genotoxic. Thus, 
the potential contribution of both genotoxic 
and non  genotoxic mechanisms to the carcino­
genicity of furan must be taken into account.
Carcinogenesis is a complex multistage 
process during which the tightly controlled 
balance between cell proliferation and cell 
death is disrupted. Furan­induced cell 
prolifera  tion and apoptosis have been found 
in mouse and rat liver (Fransson­Steen 
et al. 1997; Mugford et al. 1997; Wilson 
et al. 1992). Cell proliferation, as a neces­
sary component for tumor development, 
may influence tumor formation by increasing 
spontaneous mutations or providing a pro­
motional influence to spontaneously initiated 
cells. Additionally, secondary oxidative DNA 
damage has been associated with chronic 
inflammation after furan exposure (Hickling 
et al. 2010).
Because of the uncertainty about the rela­
tive importance of genetic and epigenetic 
mechanisms, we investigated potential effects 
of furan on gene expression in relation to cell 
cycle, apoptosis, and DNA damage, and we 
assessed potential changes in DNA methyla­
tion and microRNA (miRNA) expression. 
DNA methylation is a potentially reversible 
chemical modification of cytosine residues 
that occurs predominantly in CpG dinucleo­
tides in mammals. Cancer cells often display 
global hypo  methylation, which can cause 
genomic instability and activation of onco­
genes, whereas the promoter region of some 
specific genes, especially tumor suppressor 
genes, can be methylated, resulting in tran­
scriptional repression. DNA methylation is 
somewhat dynamic and responsive to envi­
ronmental exposures (Szyf 2007). Thus, sev­
eral nongenotoxic chemicals have been found 
to affect gene function through changes in 
DNA methylation (Bombail et al. 2004). For 
example, the non  genotoxic rodent carcino  gen 
pheno  barbital induces global hypo  methylation 
and regional hyper  methylation in rodent livers 
(Bachman et al. 2006; Phillips and Goodman 
2009). Aberrant DNA hypermethylation of 
tumor suppressor genes in human CC has 
also been frequently reported (Sandhu et al. 
2008; Yang et al. 2005). miRNAs are a group 
of regulatory RNAs of 19–22 nucleo  tides 
involved in post  transcriptional gene regu  la­
tion (Bartel 2004). miRNAs are abundant in 
the liver and play very important roles in liver 
functions (Chen 2009), and modulation of 
miRNA expression profiles is closely linked to 
the biological and clinical behavior of human 
intra  hepatic CC (Chen et al. 2009).
The aim of this study was to test the 
hypothesis that furan can modulate the expres­
sion of genes relevant to tumor induction, 
possibly through effects on DNA methyla  tion 
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Ba c k g r o u n d: Evidence of potent rodent carcinogenicity via an unclear mechanism suggests that 
furan in various foods [leading to an intake of up to 3.5 μg/kg body weight (bw)/day] may present a 
potential risk to human health.
oBjectives: We tested the hypothesis that altered expression of genes related to cell cycle control, 
apoptosis, and DNA damage may contribute to the carcinogenicity of furan in rodents. In addition, 
we investigated the reversibility of such changes and the potential role of epigenetic mechanisms in 
response to furan doses that approach the maximum estimated dietary intake in humans.
Me t h o d s : The mRNA expression profiles of genes related to cell cycle, apoptosis, and DNA damage 
in rat liver treated with furan concentrations of 0.1 and 2 mg/kg bw were meas  ured by quantitative 
polymerase chain reaction (PCR) arrays. We assessed epigenetic changes by analysis of global and 
gene-specific DNA methylation [methylation-specific PCR, combined bisulfite restriction analysis 
(COBRA), and methylated DNA immuno  precipitation chip] and microRNA (miRNA) analyses.
re s u l t s: The expression profiles of apoptosis-related and cell-cycle–related genes were unchanged 
after 5 days of treatment, although we observed a statistically significant change in the expression of 
genes related to cell cycle control and apoptosis, but not DNA damage, after 4 weeks of treatment. 
These changes were reversed after an off-dose period of 2 weeks. None of the gene expression changes 
was associated with a change in DNA methyla  tion, although we detected minor changes in the 
miRNA expression profile (5 miRNA alterations out of 349 measured) that may have contributed to 
modification of gene expression in some cases.
co n c l u s i o n: Nongenotoxic changes in gene expression may contribute to the carcinogenicity of 
furan in rodents. These findings highlight the need for a more comprehensive risk assessment of 
furan exposure in humans.
key w o r d s : carcinogenicity, DNA methylation, epigenetic, furan, gene expression, liver, miRNA. 
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or miRNA expression in rat liver. Importantly, 
we treated rats with 0.1 mg/kg bw furan, 
a dose closer to the estimated highest level 
of human exposure (3.5 μg/kg bw/day)   
(European Food Safety Authority 2004), and 
with 2 mg/kg bw furan, the lowest dose asso­
ciated with rat carcinogenicity (Maronpot 
et al. 1991). We used furan­induced CC and 
paired non  tumor tissues as reference samples 
for DNA methylation assays.
Materials and Methods
Chemicals. We obtained furan (CAS no. 
110­00­9, ≥ 99% pure) from Sigma­Aldrich 
(Munich, Germany), NovaTaq Hot Start 
DNA Polymerase (catalog no. 71091) from 
Merck (Darmstadt, Germany), and all other 
chemicals and enzymes from New England 
Biolabs (Ipswich, MA, USA) or Sigma­
Aldrich, if not mentioned otherwise. 
Animals. Male F344/N rats at 6–7 weeks 
old were purchased from Harlan­Winkelmann 
(Borchen, Germany). Animals were treated 
humanely and with regard for alleviation 
of suffering. All procedures involving ani­
mals were performed according to national 
animal welfare regulations after authoriza­
tion by the local authorities (Regierung von 
Unterfranken). All animals were given free 
access to pelleted standard rat maintenance 
diet and tap water, and were housed in groups 
of five in Makrolon cages (TECNIPLAST, 
Hohenpeißenberg, Germany) at 21 ± 2°C 
and a 12/12 hr day/night cycle. Rats were 
allowed to acclimatize for 5–7 days before 
furan treatment. Furan was prepared in corn 
oil vehicle immediately before use and was 
administered orally via gavage at doses of 
0, 0.1, and 2 mg/kg bw for 5 days, 28 days, 
and 28 days plus a 14­day recovery period, for 
a total of nine treatment groups; animals were 
treated 5 days/week. Sections of left lobes of 
the liver, including subcapsular proliferative 
regions [which have previously been shown 
to be susceptible to furan­induced tumor for­
mation (Mally et al. 2010; Maronpot et al. 
1991)] were removed, frozen in liquid nitro­
gen, and stored at –80°C.
Genomic DNA and RNA purification.   
Samples of frozen rat liver (30 mg; n = 5) were 
processed using Precellys kit 03961CK14 
(Bertin  Technologies,  Montigny­le­
Bretonneux, France) containing 0.6 mL RLT 
buffer (Qiagen, Hilden, Germany) with 6 μL 
β­mercaptoethanol. After loading on the 
Precellys 24 system (Bertin Technologies), 
samples were homogenized and centrifuged 
two times at 2,400 rpm for 10 sec. Genomic 
DNA and RNA were purified at the same 
time using the AllPrep DNA/RNA Mini Kit 
(Qiagen) according to the manufacturer’s 
instructions. Genomic DNA contamination 
was removed from purified RNA samples using 
the Turbo DNA­free kit (Applied Biosystems, 
Foster City, CA, USA). The concentrations 
of DNA and RNA were measured by ultra­
violet (UV) absorbance using a NanoDrop 
1000 Spectrophotometer (Thermo Scientific 
from Fisher Scientific, Loughborough, UK). 
The purity of DNA and RNA were deter­
mined by UV scanning between 200 and 
300 nm and by the 260:280 nm ratio. For 
DNA and RNA, the ratios were 1.8–1.9 
and 1.9–2.0, respectively. RNA quality was 
assessed by RNA gel electrophoresis.
mRNA polymerase chain reaction (PCR) 
array. One microgram of purified RNA was 
used to synthesize complementary DNA using 
the RT2 Profiler PCR Array kit (PARN­012, 
­020, and ­029; SABiosciences, Frederick, MD, 
USA). We performed real­time PCR using 
an ABI7000 PCR system and PowerSYBR 
reagents (Applied Biosystems) following the 
standard two­step cycling and dissociation 
program. Results from three different rat liver 
samples in each group were analyzed using the 
Excel­based data analysis template provided by 
SABioscience. Relative gene expression was cal­
culated using the comparative threshold cycle 
(Ct) method (2−ΔΔCt).
miRNA PCR array. We extracted total 
RNA containing miRNA from three differ­
ent rat liver samples in each group using a 
mirVana miRNA isolation kit (Applied 
Biosystems). Purified RNA (2 μg) was reverse 
transcribed into complementary DNA 
using a QuantiMir Kit (RA680A­1; System 
Biosciences, Mountain View, CA, USA). 
Real­time PCR was performed on a 384­well 
plate using an ABI7900 PCR system (Applied 
Biosystems) and a QuantiMir kit (System 
Biosciences) and PowerSYBR reagents 
(Applied Biosystems) following standard 
thermo  cycling conditions. We calculated rela­
tive miRNA expression (Ct) using the 2−ΔΔCt 
method. We used miRGen software (Megraw 
et al. 2007) and MicroCosm Targets soft­
ware (version 5; European Molecular Biology 
Laboratory, European Bioinformatics Institute 
2010) to predict miRNA targets. 
Methylation-specific PCR (MSP) and com-
bined bisulfite restriction analysis (COBRA). 
To generate positive methylated DNA con­
trols, we incubated rat genomic DNA with 
4 U M.SssI (CpG methylase) in the presence 
of S­adenosylmethionine. Bisulfite conversion 
of genomic DNA was performed using an EZ 
DNA Methylation­Gold Kit (Zymo Research, 
Orange, CA, USA) following the manufac­
turer’s protocol. Genomic DNAs (~ 400 ng) 
from five different samples in each group were 
used for bisulfite treatment. Elution volume 
was 40 μL, and 2 μL of the eluted DNA was 
used as a PCR template. PCR reactions were 
performed on a Mastercycler (Eppendorf, 
Hamburg, Germany); primers are listed in 
Supplemental Material, Table 1 (doi:10.1289/
ehp.1002153). For MSP, the PCR products 
were directly run on a 2% agarose gel. For 
COBRA, the PCR products were digested 
by the corresponding restriction enzymes and 
then run on a 2% agarose gel.
Methylated DNA immunoprecipitation 
(MeDIP) and microarray analysis. We used 
this method as an “open” unbiased system 
to detect methylation changes. Methylated 
DNA was immuno  precipitated using the 
MagMeDIP kit (mc­magme­048; Diagenode, 
Liège, Belgium). Briefly, genomic DNA puri­
fied from rat liver was sheared to 200–1,000 bp   
at 30% power for ten 15­sec pulses using 
VCX130 (Sonics, Newtown, CT, USA) and 
then incubated with anti–5­methylcytosine 
antibody at 4°C overnight. After washing 
four times, the methylated DNA­enriched 
genomic DNA faction was eluted in provided 
elution buffer. For micro  array analysis, the 
immuno  precipitated DNA and input DNA 
were amplified with a whole genome ampli­
fication kit (WGA2­50RXN; Sigma­Aldrich) 
and then were sent to NimbleGen’s service 
laboratory to perform the array experiments 
using Rat CpG Island Promoter micro  array 
(C7120­00­01; Roche NimbleGen, Madison, 
WI, USA). Data were extracted from scanned 
images using NimbleScan 2.0 extraction soft­
ware (Roche NimbleGen) and were entered 
into GeneSpring GX software (version 7.3; 
Agilent Technologies, Santa Clara, CA, USA) 
for analysis. 
Liquid chromatography/tandem mass spec-
trometry (LC-MS/MS). Global DNA methyla­
tion was detected in at least five different rat 
liver samples in each group. RNA contamina­
tion of isolated DNA was removed by treating 
with 100 μg/mL RNase A and 2,000 U/mL 
RNase T in a final volume of 100 μL at 37°C 
for 2 hr; DNA was then purified by phenol/
chloroform extraction followed by ethanol 
precipitation. Genomic DNA (5 μg) was then 
denatured at 100°C for 3 min and chilled 
on ice. After treating with 5 U nuclease P1 
(Calbiochem, Darmstadt, Germany) for 1 hr 
at 37°C, 1 U alkaline phosphatase (Sigma­
Aldrich, St. Louis, MO, USA) was added 
to the sample and incubated for 30 min at 
37°C. The hydrolyzed DNA was transferred 
onto a cutoff filter (Millipore, Billerica, MA, 
USA) and centrifuged for 20 min at 4°C and 
14,000 rpm. DNA hydrolysate (5 μL) was 
diluted with 495 μL double­distilled H2O in 
a vial. LC­MS/MS analysis was performed 
using an Agilent 1100 series LC coupled to 
an API 3000 triple quadrupole mass spec­
trometer equipped with a turbo ion spray 
source (Applied Biosystems). Separation was 
carried out on a Reprosil Pur ODS 3 column 
(150 × 2 mm, 5 μm) by gradient elution with 
0.1% formic acid (solvent A) and methanol 
(solvent B) using the following conditions: 
90% A and 10% B (starting conditions) fol­
lowed by an increase to 40% in 3 min and Furan alters gene expression but not DNA methylation
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a linear increase to 100% B in 2.5 min, at 
a flow rate of 0.3 mL/min. Analytes were 
detected in the positive ion mode at a vapor­
izer temperature of 400°C. Data acquisition 
was performed by multiple reaction monitor­
ing of mass transitions m/z 268.2 to 152.1 for 
2­deoxyguanosine, and m/z 242.17 to 126.0 
and m/z 242.17 to 108.95 for 5­methyldeoxy­
cytidine. Quantitation of 2­deoxyguanosine 
and 5­methyldeoxycytidine was performed 
using external standards.
Statistical analyses. We used the Student 
t­test to analyze PCR arrays for both mRNA 
and miRNA expression profiles; only expres­
sion changes that were statistically significant 
and at least two times higher or lower than 
expression in controls were considered. mRNAs 
and miRNAs with average Ct values > 32 
in both control and treated groups were not 
investigated further. Global DNA methyla  tion 
levels were compared using one­way analysis of 
variance followed by Dunnett’s and Tukey’s 
multiple comparison test. A p value < 0.05 was 
considered statistically significant.
Results
mRNA expression profiles of genes related 
to apoptosis, cell cycle, and DNA damage. 
Each PCR array contained 84 genes related 
to apoptosis, cell cycle, and DNA damage. 
Three genes (casp3, Bcl2, and Trp63) are 
important to both apoptosis and cell cycle 
and were included in both arrays. Twelve 
other genes were present in both cell cycle 
and DNA damage arrays. Moreover, Tp53 
and Gadd45a existed in all three arrays. Thus, 
in total, we examined 233 genes in this study 
using PCR arrays [see Supplemental Material 
(doi:10.1289/ehp.1002153)]. The expression 
of 18 genes, including Cdnk2a, was barely 
detectable in both control and treated sam­
ples (with an average Ct value > 32; data not 
shown); expression of these genes was not 
considered further.
As shown in Figure 1A and B and in 
Supplemental Material, Table 2 (doi:10.1289/
ehp.1002153), at doses 0.1 and 2 mg/kg 
bw, no genes were significantly expressed at 
levels two times higher or two times lower 
than those in controls after 5 days of furan 
treatment, with the exception of Npm2, a 
cell­cycle–related gene that showed a slight 
down­regulation (relative expression, –3.39; 
p = 0.044). In contrast a number of apopto­
sis­related and cell­cycle–related genes were 
over  expressed after 4 weeks of furan treat­
ment. Altered expression of apoptosis­related 
genes was more common after treatment at 
2 mg/kg bw than 0.1 mg/kg bw (Figure 1A; 
see also Supplemental Material, Table 2). 
However, 14 cell­cycle–related genes were 
statistically significantly up­regulated after 
furan treatment at 0.1 mg/kg bw, compared 
Figure 1. Volcano plots of relative changes in the expression of genes related to apoptosis (A), cell cycle (B), and DNA damage (C) in liver from rats treated with 
furan at 0.1 or 2 mg/kg/bw for 5 days, 4 weeks, or 4 weeks plus a 2-week recovery period (n = 3 animals per treatment group). The solid vertical line indicates a 
relative change in gene expression of 1 (i.e., no difference in expression relative to untreated controls); dashed vertical lines indicate expression levels 2 times 
higher or lower than controls; and the horizontal dash-dot line indicates the threshold for p < 0.05. For a complete list of the genes evaluated in each group, see 
Supplemental Material (doi:10.1289/ehp.1002153). 
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with only two genes after 2 mg/kg bw furan 
(Figure 1B; see also Supplemental Material, 
Table 2). All up­regulated genes returned 
to control levels of expression 2 weeks after 
withdrawal of furan treatment. For DNA­
damage–related genes, we found no change 
in mRNA expression in rat liver treated with 
furan at 2 mg/kg bw (Figure 1C). We did not 
perform DNA damage PCR arrays in samples 
treated with 0.1 mg/kg bw furan, but Brca2 
(relative expression, 2.46; p < 0.05) and Chek1 
(relative expression, 2.05; p < 0.05) genes, 
related to both cell cycle and DNA damage, 
did show slight up­regulation (Supplemental 
Material,Table 2). 
miRNA expression profiles. Of the 
349 miRNA we examined, 64 had average Ct 
values > 32 in both control and treated sam­
ples [see Supplemental Material (doi:10.1289/
ehp.1002153)]; we did not further consider 
expression of these genes. As shown in Table 1, 
expression of 13 miRNAs was > 2 times higher 
or lower than in controls (p < 0.05), including 
only two miRNAs (rno­let­7a and rno­miR­28) 
that were up­regulated. Using miRGen and 
MicroCosm, we found that Ccna2 and Bcl10, 
two genes that were up­regu  lated in our 
mRNA arrays, were the predicted targets of the 
down­regulated rno­miR­489 and rno­let­7e*, 
respectively. E2f1, which was significantly 
up­regulated after treatment with 0.1 mg/kg 
bw furan, was the predicted target of down­ 
regulated rno­miR­296.
Analysis of DNA methylation of selected 
genes. To determine if there was any methyla­
tion change in furan­treated samples at 
the 2 mg/kg bw dose, we first examined 
the methylation status of five genes rele­
vant to carcinogenesis: p16INK4a, p15INK4b 
(Cdkn2b), Bid3 (BH3 interacting domain), 
Myc (myelocytomatosis oncogene), and Sfn 
(stratifin, also known as 14­3­3 sigma). Two 
of these genes (p15INK4b and Bid3) were up­
regulated in furan­treated rat liver samples 
based on mRNA PCR arrays, consistent with 
the hypothesis that methylation may, in part, 
contribute to the mechanism of action. Myc 
is an oncogene, whereas Sfn, p16INK4a, and 
p15INK4b are tumor suppressor genes. MSP 
results shown in Figure 2A and B demonstrate 
that both p16INK4a and p15INK4b promoter 
regions were unmethylated in all control and 
treated samples, and only a very small propor­
tion of Myc promoter region was methylated. 
COBRA results (Figure 2C) further proved 
the low methylation status of Myc promoter 
in both control and treated rat liver. Lack of 
methylation of Bid3 and methyla  tion of Sfn 
in all control and treated samples were also 
demonstrated in COBRA results (Figure 2D). 
Overall, we found no furan­induced DNA 
methylation changes in the selected genes. 
MeDIP and DNA methylation micro  array 
results. To screen for alternative genes with 
potential methylation alteration, we conducted 
MeDIP and micro  array experiments.We 
focused on the 2 mg/kg bw furan treatment 
group because this dose can induce CC after 
2 years of treatment (Maronpot et al. 1991). 
R. Maronpot kindly provided a furan­induced 
CC sample from a female Sprague­Dawley rat 
treated with 2 mg/kg bw furan for 500 days 
that we used as a reference sample and in which 
we found modulation of methylation. 
After immunoprecipitation, we examined 
the enrichment of four single­copy genes as 
well as the positive and negative controls pro­
vided in the Diagenode MeDIP kit to confirm 
the enrichment of methylated DNA by anti–5­
­methylcytosine antibody. The hypo  methyla­
tion status of Myc gene promoter region was 
independently shown by MSP and COBRA 
(Figure 2A,C), whereas the 5´­upstream 
region of the H19 gene has been found to be 
highly methylated in the adult rat by bisulfite 
sequencing (Manoharan et al. 2004). Thus, 
Myc and H19 could be employed as negative 
and positive controls, respectively. We also 
investigated the enrichment rate of LINE­1 
(long interspersed nucleotide element type 1) 
and ID (identifier) elements because repet­
itive elements represent a large part of the 
genomes and can reflect global methylation 
level to some extent. ID elements are mem­
bers of a family of SINEs (short interspersed 
nucleotide elements) in rodents. We speculate 
Table 1. miRNAs with > 3-fold significant expres-
sion change in liver of rats treated with furan at 
2 mg/kg bw for 4 weeks.
miRNA p-Value
Change relative 
to controls
rno-let-7a 0.0061 2.63
rno-let-7e* 0.0459 –2.05
rno-miR-28 0.0132 3.08
rno-miR-129* 0.0159 –2.39
rno-miR-187 0.0273 –2.23
rno-miR-207 0.0076 –4.09
rno-miR-298 0.0311 –2.06
rno-miR-296 0.0448 –7.93
rno-miR-376b-3p 0.0438 –2.44
rno-miR-488 0.0220 –2.07
rno-miR-489 0.0325 –3.55
rno-miR-493 0.0063 –5.64
rno-miR-598–5p 0.0173 –2.47
Figure 2. DNA methylation status of p16INK4a, p15INK4b, Myc, Bid3, and Sfn promoter region in liver samples from control rats (C1, C2) or rats treated with furan 
(2 mg/kg bw for 4 weeks; T1, T2) (n = 5 rats). MSP profiles of p16INK4a and Myc promoter region (A) and p15INK4b promoter (B). COBRA results of c-myc gene 
digested by TaqI 241 bp (40/77/125) (C), Bid3 gene digested by BstUI 310 bp (210/68/32) (D), and Sfn gene digested by TaqI 229 bp (56/173) (E). Abbreviations: bp, 
base pairs; C, cleaved PCR products; M100, 100-bp DNA ladder (New England Biolabs); Me, methylated rat genomic DNA treated with methyltransferase (M.SssI); 
MV, HyperLadder V (Bioline, Luckenwalde, Germany); UM, uncleaved PCR products. 
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that cytosines lie within the CpG islands of 
the transposons, including LINE and SINE. 
Only the H19 gene and the positive internal 
control were enriched in immuno  precipitated 
DNA [see Supplemental Material, Figure 1 
(doi:10.1289/ehp.1002153)]. LINE­1 showed 
little enrichment, which is consistent with a 
previous report that LINE­1 was hypomethy­
lated in rat liver (Asada et al. 2006). Although 
the methylation level of one CpG of ID ele­
ments has been reported at > 60% (Kim 
et al. 2007), considering the high mutation 
level and the possible low methylation status 
of other CpG sites, it is not surprising that 
few ID elements were enriched in immuno­
precipitated DNA.
We found no evident methylation change 
in samples treated with furan for 4 weeks 
compared with control samples by the micro­
array method. However, when validating the 
assay, we noted methylation changes in pro­
moter regions of the CC sample relative to 
paired normal liver samples (data not shown).
Global DNA methylation. We observed 
no significant global methylation change 
in either furan treatment group (Figure 3). 
However, CC samples showed slight but sig­
nificant hypomethylation levels compared 
with non  tumor samples (p < 0.01; Figure 3). 
Global methylation in mammals usually 
ranges from 3% to 5% (Bombail et al. 2004; 
Özden et al. 2008), in agreement with our 
findings.
Discussion
We assessed gene expression changes and epi­
genetic parameters relevant to carcinogenesis 
at furan doses lower than the minimum dose 
that has been shown to cause tumors, and 
closer to estimated exposure levels in humans. 
Although treatment with 2 mg/kg bw furan 
for 5 days did not appear to influence gene 
expression, we observed statistically signifi­
cant expression changes in the expression of 
a number of apoptosis­related and cell­cy­
cle–related genes after 4 weeks of treatment 
with 0.1 mg/kg bw furan. We also found that 
changes in gene expression following 4 weeks 
of treatment with 2 mg/kg bw furan were 
reversed 2 weeks after furan treatment was 
discontinued, which suggests that sustained 
exposure to furan is required to elicit effects 
at relatively low doses. Consistent with this, 
Hamadeh et al. (2004) reported a significant 
gene expression difference between 2­week 
exposure and 3­ or 7­day exposure in rats 
treated with 4 mg/kg furan. 
Although we found no DNA­damage–
related gene expression changes in samples 
from animals treated with 2­mg/kg bw furan, 
Brca2 and Chek1—two cell­cycle–related 
genes that respond to DNA double­strand 
breaks (DSBs)—showed a slight over­
expression in samples from animals treated 
with 0.1 mg/kg bw furan. cis­2­Butene­1,4­
dial, the major reactive metabolite of furan, 
has been shown to form covalent adducts with 
nucleosides in vitro (Byrns et al. 2006), and 
DSBs have been found in mitogen­stimulated 
spleno  cytes of furan­treated mice (Leopardi 
et al. 2010). High­dose (30 mg/kg bw) and 
long­term (3 months) treatment with furan 
has been found to induce oxidative stress 
and associated DNA damage (Hickling et al. 
2010). However, in the present study, which 
was shorter term and used a lower dose, we 
found no change in oxidative DNA­damage–
related gene expression, nor did we find a gene 
expression profile charac  teristic of a range of 
geno  toxic carcinogens, such as described by 
Ellinger­Ziegelbauer et al. (2005). In another 
study (Mally et al. 2010), we observed only 
a reversible enhanced proliferation in the 
subcapsular region of the left liver lobe after 
treatment with 2 mg/kg bw furan for 4 weeks, 
with little or no DNA oxidation. Considering 
that oxidative DNA damage is related to pro­
moting activity more than initiating activity 
(Ellinger­Ziegelbauer et al. 2005; Umemura 
et al. 1999), the oxidative DNA damage may 
be a secondary mechanism associated with a 
persistent inflammatory response (Hickling 
et al. 2010).
Recent studies indicate that miRNAs are 
involved in regulation of cell proliferation and 
apoptosis (Ambros 2004). Moreover, miRNA 
expression profiles have been closely associ­
ated with the biological and clinical behav­
ior of human intra  hepatic CC (Chen et al. 
2009). Thus, altered miRNA expression might 
contribute to the deregulation of certain cell­
cycle–related and apoptosis­related genes. 
Here we found that 13 of the 349 miRNAs 
examined were aberrantly expressed in sam­
ples from the 2­mg/kg–treated animals, and 
two down­regulated miRNAs (rno­let­7e* and 
rno­miR­489) were consistent with the up­ 
regulation of mRNA expression of their pre­
dicted target genes, Bcl10 and Ccna2. The let‑7 
family of miRNAs, which is functionally con­
served from worms to humans, is important to 
normal development and differentiation and 
has been reported to be deregulated in various 
cancers (reviewed by Boyerinas et al. 2010). 
For example, let‑7e* was down­regulated in 
malignant mesothelioma (Guled et al. 2009), 
and let‑7a was up­regulated in lung, lym­
phoma, and ovarian cancers (Boyerinas et al. 
2010). Caspase‑3, Dicer, and Myc have been 
confirmed to be let‑7a targets (Boyerinas et al. 
2010). In the present study, rno­miR­296 
showed the greatest change in expression 
(~ 8­fold down­regulation). Human miR‑296 
has been reported to be down­regulated in 
breast cancer and para  thyroid cancer (Barh 
et al. 2008; Corbetta et al. 2010). Furthermore, 
inhibition of miR­296 in Hela cells has been 
reported to decrease cell growth and increase 
the level of apoptosis (Cheng et al. 2005).
Changes in DNA methylation consti­
tute a mechanism for altering gene expression 
and are important non  genotoxic mechanisms 
contributing to cancer. In the present study, 
we investigated the methylation status of five 
genes (p16INK4a, p15INK4b, Bid3, Myc, and 
Sfn) in samples from rats treated with furan at 
2 mg/kg bw. Promoter methylation changes 
of p16INK4a, p15INK4b, and Sfn have been 
reported in CC (Lee et al. 2002; Yang et al. 
2005), and hypomethylation­induced Myc 
over  expression has been found in various types 
of tumors (Del Senno et al. 1989; Tao et al. 
2002; Tsujiuchi et al. 1999). However, in the 
present study, we found no DNA methylation 
change in the five genes evaluated by MSP 
and/or COBRA. Furthermore, we found no 
methylation changes using the “open” unbiased 
method of MeDIP and micro  array assay using 
NimbleGen’s Rat CpG Island Promoter micro­
array, which covers 15,809 islands and 14,490 
promoters. In addition, we did not observe 
evidence of a global methyla  tion change based 
on LC­MS/MS. Taken together, these results 
suggest that the reversible gene expression 
changes we observed were not caused by meth­
ylation changes. The findings contrast with 
the observation of irreversible gene expression 
changes, a DNA damage response, and altered 
methyla  tion of at least one gene in liver sam­
ples from rats treated with a much higher furan 
dose of 30 mg/kg bw for 3 months (Hickling 
et al. 2010; Chen T, Williams T, Mally A, 
Hamberger C, Hickling K, Chipman JK, 
unpublished data).
Conclusion
Short­term treatment with furan at a dose 
approaching the maximum estimated human 
dietary intake resulted in reversible changes 
in the expression of genes that control the 
cell cycle and cell death but did not appear 
to influence the expression of genes involved 
in responses to DNA damage. These changes 
did not appear to result from changes in DNA 
methylation, although modulation of miRNA 
may have a minor role in these responses. 
Bearing in mind the demonstrated differen­
tial profile of gene expression of genotoxic 
and non  genotoxic carcinogens in rodent liver 
Figure 3. Global methylation level in liver samples 
from furan-treated rats (n = 5 animals per treatment 
group). 
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(Ellinger­Ziegelbauer et al. 2005), the cell 
cycle and apoptotic responses we observed 
may provide a nongenotoxic influence on 
carcinogenesis at furan doses lower than the 
currently identified lowest carcinogenic dose. 
Further related studies on low doses of furan 
are under way by the NTP (2008). 
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